Format

Send to

Choose Destination
Urol Oncol. 2008 Nov-Dec;26(6):595-9. doi: 10.1016/j.urolonc.2007.07.013. Epub 2008 Jan 14.

Malignant transformation of testicular teratoma: a chemoresistant phenotype.

Author information

1
Department of Urologic Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.

Abstract

PURPOSE:

To review our experience in the management of malignant transformation of teratoma (MTT).

MATERIALS AND METHODS:

Nine patients with MTT were identified from January 1980 to August 2005, with all pathological specimens re-reviewed by a single genitourinary pathologist.

RESULTS:

Two patients presented with clinical stage I disease in which malignant transformation occurred within the primary testis tumor (rhabdomyosarcoma in 1 and adenocarcinoma in 1). These patients underwent a primary retroperitoneal lymph node dissection (RPLND). No viable tumor was identified in the specimen, and both patients were alive without disease at 16 months follow-up. Of the remaining 7 patients, the clinical stages were IIA (N = 1), IIB (N = 3), and III (N = 3), and all were treated with chemotherapy followed by RPLND. The MTT histology of these RPLND specimens consisted of adenocarcinoma (N = 3), rhabdomyosarcoma (N = 2), angiosarcoma (N = 1), and astrocytoma (N = 1). Following preoperative chemotherapy, a significant radiologic response (defined as more than a 25% reduction in maximum tumor circumferential diameter) was demonstrated in 1 patient, and normalization of serum tumor markers was demonstrated in 6. At a mean follow-up of 5 years, 3 of these 7 patients were alive with no evidence of disease, 1 had persistent disease, and 3 had died of disease, and their median disease-specific survival duration was 4.6 years.

CONCLUSIONS:

In our experience, MTT is significantly resistant to current chemotherapeutic regimens, as demonstrated by its poor radiologic response to treatment. Alternative therapeutic strategies targeted to MTT are thus needed.

PMID:
18367105
PMCID:
PMC4121060
DOI:
10.1016/j.urolonc.2007.07.013
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center